Mallory, R. M., Formica, N., Pfeiffer, S., Wilkinson, B., Marcheschi, A., Albert, G., McFall, H., Robinson, M., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, B., Chau, G., Robertson, A., Maciejewski, S., Hammond, H. L., Baracco, L., Logue, J., Frieman, M. B., Smith, G., Patel, N., Glenn, G. M., , , Adams, M., Arya, M., Athan, E., Berger, I., Bradley, P., Briskin, T., Glover II, R., Griffin, P., Kim, J., Kitchener, S., Klein, T., Leah, A., Leelasena, I., Lemech, C., Lickliter, J., Manning, M. B., Napier-Flood, F., Nugent, P., Thackwray, S., & Turner, M. (2022). safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet infectious diseases, 22(11), 1565–1576. http://access.bl.uk/ark:/81055/vdc_100168599634.0x000012